About Interferon regulatory factor 5
Interferon regulatory factor 5 (IRF5) is a protein
from Homo sapiens identified by UniProt accession
Q13568, 498 residues long.
MolForge cross-references it against 0 known binders and
340 disease associations.
Target properties
| Protein name | Interferon regulatory factor 5 |
| UniProt accession | Q13568 |
| Gene | IRF5 |
| Organism | Homo sapiens |
| Length | 498 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (340)
Diseases linked to this target (Open Targets).
- rheumatoid arthritis · score 0.50
- systemic lupus erythematosus · score 0.46
- inflammatory bowel disease · score 0.44
- eosinophil count · score 0.40
- Sjogren syndrome · score 0.40
- lymphocyte count · score 0.36
- ulcerative colitis · score 0.36
- systemic scleroderma · score 0.35
- autoimmune disease · score 0.34
- platelet count · score 0.34
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q13568-F1 | alphafold | PREDICTED | 72.62 | — |
Amino-acid sequence (498 residues)
MNQSIPVAPT PPRRVRLKPW LVAQVNSCQY PGLQWVNGEK KLFCIPWRHA TRHGPSQDGD NTIFKAWAKE TGKYTEGVDE ADPAKWKANL RCALNKSRDF RLIYDGPRDM PPQPYKIYEV CSNGPAPTDS QPPEDYSFGA GEEEEEEEEL QRMLPSLSLT EDVKWPPTLQ PPTLRPPTLQ PPTLQPPVVL GPPAPDPSPL APPPGNPAGF RELLSEVLEP GPLPASLPPA GEQLLPDLLI SPHMLPLTDL EIKFQYRGRP PRALTISNPH GCRLFYSQLE ATQEQVELFG PISLEQVRFP SPEDIPSDKQ RFYTNQLLDV LDRGLILQLQ GQDLYAIRLC QCKVFWSGPC ASAHDSCPNP IQREVKTKLF SLEHFLNELI LFQKGQTNTP PPFEIFFCFG EEWPDRKPRE KKLITVQVVP VAARLLLEMF SGELSWSADS IRLQISNPDL KDRMVEQFKE LHHIWQSQQR LQPVAQAPPG AGLGVGQGPW PMHPAGMQ
Explore Interferon regulatory factor 5 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets